Interview: Paul Neyman, Co-Founder and Chief Revenue Officer of Areti Health

Why It Matters

By accelerating enrollment and reducing screen‑failure rates, Areti cuts trial costs, speeds therapeutic breakthroughs, and expands patient access to experimental treatments.

Key Takeaways

• AI reads 185 documents per patient in five minutes
• 250M records accessed, matches candidates instantly
• Recruitment time cut from months to weeks
• Screen failure rate dropped from 98% to 55%
• 24/7 personalized outreach reduces patient drop‑off

Pulse Analysis

Clinical‑trial recruitment has long been a choke point for drug developers, with fragmented outreach and manual chart reviews causing patients to fall through the cracks and sponsors to incur costly delays. Traditional site staff juggle dozens of studies, often relying on phone calls that miss busy patients, leading to enrollment shortfalls that can extend timelines by months. The resulting inefficiencies not only inflate R&D budgets but also postpone potentially life‑saving therapies from reaching the market.

Areti Health tackles this problem with a generative‑AI engine that ingests complete electronic health records—lab results, prescriptions, imaging reports, and physician notes—using advanced natural‑language processing. Within five minutes, the system maps unstructured data against trial protocols, delivering graded eligibility scores and transparent citations for each decision. Its agentic engagement layer reaches patients via preferred channels—text, email, or voice—delivering personalized, 24/7 conversations that guide them from initial interest through digital consent, all while staying within IRB‑approved scripts and regulatory constraints.

The business impact is measurable: recruitment cycles shrink from months to weeks, screen‑failure rates drop dramatically, and patient drop‑off declines thanks to continuous, empathetic outreach. Areti now launches an average of four studies weekly, handling thousands of leads across therapeutic areas such as Alzheimer’s, dermatology, and COVID‑19. As sponsors seek faster, cheaper paths to market, AI‑driven enrollment platforms like Areti are poised to become essential infrastructure, reshaping how clinical research connects with patients and accelerating the delivery of innovative treatments.